ImmunityBio, Inc. (IBRX)
11.54
+1.71
(+17.40%)
USD |
NASDAQ |
Feb 24, 16:00
11.78
+0.24
(+2.08%)
After-Hours: 20:00
ImmunityBio Cash from Financing (TTM) : 452.28M for Sept. 30, 2025
Cash from Financing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (TTM) Benchmarks
| Novavax, Inc. | 30.92M |
| Krystal Biotech, Inc. | 8.705M |
| Rapt Therapeutics, Inc. | 143.31M |
| Moderna, Inc. | 593.00M |
| Corcept Therapeutics, Inc. | -193.71M |